1 week Ago By ABMN Staff
Marino Stram & Associates LLC lowered its holdings in Johnson & Johnson ( NYSE:JNJ – Free Report ) by 7.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,111 shares of the company’s stock after selling 1,173 shares during the quarter.
Marino Stram & Associates LLC’s holdings in Johnson & Johnson were worth $2,185,000 as of its most recent SEC filing. A number of other hedge funds have also modified their holdings of JNJ. IFS Advisors LLC boosted its position in shares of Johnson & Johnson by 138.
9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $31,000.
RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in Johnson & Johnson by 58.7% during the third quarter.
Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $40,000. 69.
55% of the stock is currently owned by hedge funds and other institutional investors. Insider Transactions at Johnson & Johnson In related news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th.
The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00.
Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website .
Insiders own 0.16% of the company’s stock. Johnson & Johnson Stock Up 0.
1 % Johnson & Johnson ( NYSE:JNJ – Get Free Report ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.
99 by $0.05. The business had revenue of $22.
52 billion during the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.
20%. The company’s revenue was up 5.3% compared to the same quarter last year.
During the same period in the prior year, the company earned $2.29 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.
56 EPS for the current year. Johnson & Johnson Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.
24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.
96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson’s payout ratio is 74.
59%. Analyst Upgrades and Downgrades JNJ has been the topic of several recent research reports. StockNews.
com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Bank of America reduced their price objective on Johnson & Johnson from $160.00 to $159.
00 and set a “neutral” rating on the stock in a research note on Thursday. Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.
00 and set an “outperform” rating for the company in a research note on Thursday. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday.
Finally, Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday.
Nine analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $170.06.
Read Our Latest Research Report on JNJ Johnson & Johnson Profile ( Free Report ) Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ). Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.
com's FREE daily email newsletter ..
